Close

BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update At BIO CEO & Investor Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...
- Advertisement -

BioSante Pharmaceuticals, Inc. will be presenting at the 2011 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual CEO & Investor Conference will take place February 14-15, 2011 at the Waldorf-Astoria in New York. Stephen M. Simes, BioSante’s president & CEO, will speak today, Monday February 14, 2011 at 3:30 pm EST. He will provide an overview of the company, as well as an update on LibiGel® (testosterone gel) Phase III clinical development program including safety data. A live audio webcast of Mr. Simes’ remarks may be accessed at: http://www.veracast.com/webcasts/bio/ceoinvestor2011/16113289.cfm.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »